| Field | Specification |
|---|---|
| UniProt # | |
| Applications | |
| Sensitivity | |
| Detection range | |
| Detection method | |
| Assay time | |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Scientific Background
This ELISA kit applies to the in vitro quantitative determination of Human GDF15 concentrations in serum, plasma and other biological fluids.
Assay Principle
This ELISA kit uses the Sandwich-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Human GDF15. Standards or samples are added to the micro ELISA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Human GDF15 and Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human GDF15, biotinylated detection antibody and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The OD value is proportional to the concentration of Human GDF15. You can calculate the concentration of Human GDF15 in the samples by comparing the OD of the samples to the standard curve.
Performance Specifications
| Sensitivity | 14.06 pg/mL |
|---|---|
| Detection Range | 23.44-1500 pg/mL |
| Total Assay Time | 3 h 30 min |
| Compatible Sample Types | Serum, plasma and other biological fluids |
| Species Reactivity | Human |
| Detection Method | Sandwich |
| Precision (CV) | Both intra-CV and inter-CV are < 10%. |
| Recovery Rate | 80%-120% |
| Storage | 2-8℃,12 months |
✓ Research-Grade Validation
Specificity
This kit recognizes Human GDF15 in samples. No significant cross-reactivity or interference between Human GDF15 and analogues was observed
Safety & Regulatory
Handle reagents in accordance with institutional biosafety guidelines. Refer to the Safety Data Sheet (SDS) for complete hazard and handling information. Contains components that may require special disposal procedures per local regulations.
This kit is validated for use with Serum, plasma and other biological fluids. For unlisted matrices (e.g., tissue lysate, urine), perform a spike-and-recovery experiment to confirm assay performance before generating reportable data. Sample dilution in the kit's provided diluent is recommended to minimize matrix interference.
The minimum detectable concentration (sensitivity) of this kit is 14.06 pg/mL. Values below this threshold should be reported as below the limit of detection (<LOD) and should not be extrapolated from the standard curve.
The total assay time from sample addition to absorbance reading is approximately 3 h 30 min, including all incubation, wash, and substrate steps. Hands-on time is typically 1–2 hours; most steps involve passive plate incubation. Plan the assay as a single uninterrupted session for best results.
Standard components of this Sandwich ELISA Kit typically include: pre-coated microplate (96-well strip format), lyophilized or liquid recombinant GDF15 standard, detection antibody, streptavidin-HRP conjugate, TMB substrate, stop solution, wash buffer concentrate, and sample/standard diluent. Refer to the kit insert or datasheet for the exact component list and storage requirements.
This kit uses colorimetric (TMB/HRP) detection and requires a standard microplate absorbance reader capable of measuring at 450 nm. A reference wavelength of 570 nm or 630 nm is recommended to reduce background. No specialized fluorescence or luminescence reader is needed. Ensure the instrument is calibrated and the plate is clean and free of condensation before reading.
Tissue samples may contain endogenous or exogenous proteases during processing, leading to degradation of extracted proteins. Therefore, it's necessary to add protease inhibitors during processing to ensure the integrity of target proteins. If customers can keep samples cold and handle them quickly during processing, omitting the protease inhibitor may not have a significant effect. After preparation, samples should be tested promptly or immediately aliquoted and frozen at -20°C or -80°C.
What is the range of enzyme activity of your IL-2 freeze-dried powder
What is the principle of adding stop solution to stop color reaction in ELISA experiment?
Can’t Find What You’re Looking For? We can help you source the best match or customize an ELISA solution for your study. Options may include alternative target synonyms, different species reactivity, sample type/matrix compatibility (serum/plasma/lysate/supernatant), assay format (sandwich/competitive), sensitivity/range, detection chemistry (colorimetric/fluorescent/chemiluminescent), plate format (pre-coated/uncoated, strips vs full plate), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
Circulating Growth Differentiation Factor 15 (GDF15) in Paediatric Disease: A Systematic Review (2025) Journal of Cachexia Sarcopenia and Muscle. 10.1002/jcsm.13712
Colchicine Blocks Abdominal Aortic Aneurysm Development by Maintaining Vascular Smooth Muscle Cell Homeostasis (2024) International Journal of Biological Sciences. 10.7150/ijbs.93544
Matrix-Bound EGF Promotes Malignant Phenotypes of Breast Cancer Organoids in the Biomimetic ECM of Alginate (2025) Materials Today Bio. 10.1016/j.mtbio.2025.101818
Mitochondrial metabolism related markers GDF-15, FGF-21, and HIF-1α are elevated in pediatric migraine attacks (2023) HEADACHE. 10.1111/head.14618
Influence of CReatine Supplementation on mUScle Mass and Strength After Stroke (ICaRUS Stroke Trial): A Randomized Controlled Trial (2024) Nutrients. 10.3390/nu16234148
GDF-15 is a potential candidate biomarker for an elevated risk of cardiotoxicity in breast cancer patients receiving neoadjuvant dual anti-HER2 therapy (2024) Frontiers in Pharmacology. 10.3389/fphar.2024.1396133
Elevated growth differentiation factor-15 in sepsis: clinical associations and immune cell context (2026) Frontiers in Cell and Developmental Biology. 10.3389/fcell.2026.1789747
Novel Roles of GDF15 in Alleviating Renal Fibrosis: Promoting Autophagy and Lysosome Biogenesis via Inhibition of the PI3K/Akt/mTOR Pathway (2025) JOURNAL OF CELLULAR AND MOLECULAR MEDICINE. 10.1111/jcmm.70951
Serum growth differentiation factor-15 (GDF-15) is a biomarker of cardiac manifestations in children with COVID-19 (2023) EUROPEAN JOURNAL OF MEDICAL RESEARCH. 10.1186/s40001-023-01514-8
Association Between Serum HBV DNA Levels and CCL-20, CD8a, CXCL-16, and GDF-15 in Patients with Chronic Hepatitis B (2025) Viruses-Basel. 10.3390/v17101352
Evaluation of Arterial Stiffness Parameters and the Growth Differentiation Factor-15 Level in Patients with Premature Myocardial Infarction (2023) Journal of Personalized Medicine. 10.3390/jpm13101489
Prediction of progressive pulmonary fibrosis in patients with anti-synthetase syndrome-associated interstitial lung disease (2023) CLINICAL RHEUMATOLOGY. 10.1007/s10067-023-06570-3
Evaluation of cardiovascular risk by growth-differentiation factor-15 and tissue Doppler imaging in children with subclinical hypothyroidism (2019) ENDOCRINE. 10.1007/s12020-019-01933-w
Development of a nomogram for predicting incident heart failure and all-cause mortality in patients with chronic kidney disease: a 3-year follow-up study (2026) Frontiers in Medicine. 10.3389/fmed.2026.1784717
Metabolic and mitochondrial alterations in children with autism spectrum disorder: The role of FGF-21 and GDF-15 (2026) CLINICA CHIMICA ACTA. 10.1016/j.cca.2026.120979
Modulation of HMGB1, PRF1, TRAIL, and M-CSF after TARGIT-IORT in breast-conserving surgery: defining a unique acute immune landscape (2026) Clinical & Translational Oncology. 10.1007/s12094-026-04353-1
Comparative Analyses Between Vulnerability Biomarkers of Aging and Health Biomarkers in Middle-Aged and Older Female Adults (2025) Healthcare. 10.3390/healthcare13060667
Comparison of the Cytokine Profile in Mesenchymal Stem Cells from Human Adipose, Umbilical Cord, and Placental Tissues (2021) Cellular Reprogramming. 10.1089/cell.2021.0043
Growth Differentiation Factor-15 Level and Tissue Doppler Echocardiography as a Tool in Identification of Cardiac Effects in the Children with Type 1 Diabetes Mellitus (2019) EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES. 10.1055/a-0983-1673
Additional Diagnostic Value of Growth Differentiation Factor-15 (GDF-15) to N-Terminal B-Type Natriuretic Peptide (NT-proBNP) in Patients with Different Stages of Heart Failure (2018) MEDICAL SCIENCE MONITOR. 10.12659/MSM.910671
Evaluation of some nonroutine cardiac biomarkers among adults and children with beta-thalassemia major (2024) LABORATORY MEDICINE. 10.1093/labmed/lmae007
Increased serum concentrations of growth differentiation factor-15 in children with acute rheumatic fever (2022) CARDIOLOGY IN THE YOUNG. 10.1017/S1047951122001640
Assessment of serum tenascin-C and growth differentiation factor-15 among type 2 diabetes mellitus patients with and without acute coronary syndrome (2020) Journal of Medical Biochemistry. 10.5937/jomb0-24662
